{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T07:58:04Z","timestamp":1784447884778,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022310046"],"award-info":[{"award-number":["10140022310046"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BeterKeten"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sepsis and septic shock are significant global healthcare challenges with high mortality rates. Effective management requires timely and adequate antimicrobial therapy. Beta-lactam antibiotics, commonly used in patients with sepsis, are crucial for treating these infections. However, standard dosing often leads to insufficient plasma levels due to dynamic physiological changes in critically ill patients.<\/jats:p>\n                    <jats:p>Previous randomized controlled trials highlighted the need for timely dose adjustments to improve clinical outcomes. This is the study protocol for the BULLSEYE trial in which we aim to optimize antibiotic treatment during the initial 48\u00a0h of sepsis by comparing standard to double dosing of beta-lactam antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, multicenter, randomized controlled trial will compare standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin\/clavulanic acid, flucloxacillin, meropenem, and piperacillin\/clavulanic acid) in critically ill patients with septic shock. Participants will be randomized into two arms: the control arm receiving standard care, and the intervention arm receiving double antibiotic doses for 48\u00a0h, irrespective of renal function. Following this period, all patients will receive standard doses as per local protocol. The primary outcome is all cause 28-day mortality, with secondary outcomes including 90-day, 365-day, hospital and ICU mortality, hospital and ICU length of stay, SOFA scores, time to shock reversal, microbiological eradication, clinical cure, pharmacodynamic target attainment, safety, quality of life, and medical consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The BULLSEYE trial aims to improve sepsis treatment in critically ill patients. Despite anticipated recruitment challenges, its large sample size ensures robust comparability. This pivotal trial could significantly impact sepsis treatment, leading to better clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU_CT 2024\u2013512950-13\u201300. Protocol version 2.3, protocol date 09\u201312-2024. Prospectively registered on 09\u201301-2025 at Clinicaltrails.gov nr. NCT06766461.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-10747-3","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T14:12:22Z","timestamp":1742566342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"M. M. B.","family":"Horstink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"den Uil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. E.","family":"Deetman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Endeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J. R.","family":"Rietdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. W.","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Haringman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Rijpstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bethlehem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Beishuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of The BULLSEYE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Boly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A","family":"den Uil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Van Haren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Buter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Nutma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Elderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Vloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.J","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.G.M","family":"Hunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Juffermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Zwinkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"4","key":"10747_CR1","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1186\/cc2858","volume":"8","author":"A van Gestel","year":"2004","unstructured":"van Gestel A, Bakker J, Veraart CP, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. Crit Care. 2004;8(4):R153\u201362.","journal-title":"Crit Care"},{"issue":"7","key":"10747_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","volume":"29","author":"DC Angus","year":"2001","unstructured":"Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303\u201310.","journal-title":"Crit Care Med"},{"issue":"16","key":"10747_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"10747_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00134-001-1143-z","volume":"28","author":"C Alberti","year":"2002","unstructured":"Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28(2):108\u201321.","journal-title":"Intensive Care Med"},{"issue":"9","key":"10747_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1164\/rccm.200812-1912OC","volume":"180","author":"R Ferrer","year":"2009","unstructured":"Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180(9):861\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10747_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"JL Vincent","year":"2006","unstructured":"Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344\u201353.","journal-title":"Crit Care Med"},{"key":"10747_CR7","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.2147\/IDR.S390947","volume":"16","author":"EC van der Slikke","year":"2023","unstructured":"van der Slikke EC, Beumeler LFE, Holmqvist M, Linder A, Mankowski RT, Bouma HR. Understanding Post-Sepsis Syndrome: How Can Clinicians Help? Infect Drug Resist. 2023;16:6493\u2013511.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10747_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-024-04816-3","volume":"28","author":"ECN Luijks","year":"2024","unstructured":"Luijks ECN, van der Slikke EC, van Zanten ARH, Ter Maaten JC, Postma MJ, Hilderink HBM, et al. Societal costs of sepsis in the Netherlands. Crit Care. 2024;28(1):29.","journal-title":"Crit Care"},{"key":"10747_CR9","doi-asserted-by":"crossref","unstructured":"Gatti M, Cojutti PG, Pea F. Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care. 2024;28(1):123.","DOI":"10.1186\/s13054-024-04911-5"},{"issue":"12","key":"10747_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.2174\/138920111798808446","volume":"12","author":"AA Udy","year":"2011","unstructured":"Udy AA, Putt MT, Boots RJ, Lipman J. ARC\u2013augmented renal clearance. Curr Pharm Biotechnol. 2011;12(12):2020\u20139.","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"10747_CR11","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc10441","volume":"15","author":"J Goncalves-Pereira","year":"2011","unstructured":"Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care. 2011;15(5):R206.","journal-title":"Crit Care"},{"issue":"1","key":"10747_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","volume":"24","author":"A Abdulla","year":"2020","unstructured":"Abdulla A, Dijkstra A, Hunfeld NGM, Endeman H, Bahmany S, Ewoldt TMJ, et al. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Crit Care. 2020;24(1):558.","journal-title":"Crit Care"},{"issue":"8","key":"10747_CR13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10747_CR14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","volume":"48","author":"TMJ Ewoldt","year":"2022","unstructured":"Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, et al. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med. 2022;48(12):1760\u201371.","journal-title":"Intensive Care Med"},{"issue":"1","key":"10747_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","volume":"20","author":"A Abdulla","year":"2020","unstructured":"Abdulla A, Ewoldt TMJ, Hunfeld NGM, Muller AE, Rietdijk WJR, Polinder S, et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC Infect Dis. 2020;20(1):57.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10747_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/cid\/ciad215","volume":"77","author":"WJR Rietdijk","year":"2023","unstructured":"Rietdijk WJR, Drager S, Endeman H, Koch BCP. Beta-lactam Therapeutic Drug Monitoring in Critically ill Patients: Learnings for Future Research. Clin Infect Dis. 2023;77(4):663\u20134.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10747_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106931","volume":"62","author":"TMJ Ewoldt","year":"2023","unstructured":"Ewoldt TMJ, Abdulla A, Rietdijk WJR, Hunfeld N, Muller AE, Endeman H, et al. Which patients benefit from model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin at the ICU? Int J Antimicrob Agents. 2023;62(4): 106931.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10747_CR18","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10096-018-3357-9","volume":"37","author":"S Imani","year":"2018","unstructured":"Imani S, Buscher H, Day R, Gentili S, Jones GRD, Marriott D, et al. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric beta-lactam therapy. Eur J Clin Microbiol Infect Dis. 2018;37(11):2171\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10747_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jac\/dkv412","volume":"71","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Brinkmann A, Frey OR, Roehr AC, Luque S, Grau S, et al. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? J Antimicrob Chemother. 2016;71(3):696\u2013702.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10747_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s13054-019-2621-4","volume":"23","author":"C Carrie","year":"2019","unstructured":"Carrie C, Chadefaux G, Sauvage N, de Courson H, Petit L, Nouette-Gaulain K, et al. Increased beta-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study. Crit Care. 2019;23(1):379.","journal-title":"Crit Care"},{"issue":"8","key":"10747_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):775\u201387.","journal-title":"JAMA"},{"issue":"7","key":"10747_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2019.0071","volume":"321","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA. 2019;321(7):654\u201364.","journal-title":"JAMA"},{"key":"10747_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jchromb.2017.06.014","volume":"1060","author":"A Abdulla","year":"2017","unstructured":"Abdulla A, Bahmany S, Wijma RA, van der Nagel BCH, Koch BCP. Simultaneous determination of nine beta-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:138\u201343.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"7","key":"10747_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819\u201327.","journal-title":"Lancet Infect Dis"},{"key":"10747_CR25","doi-asserted-by":"crossref","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707\u201310.","DOI":"10.1007\/BF01709751"},{"issue":"1","key":"10747_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13054-017-1609-1","volume":"21","author":"HJ de Grooth","year":"2017","unstructured":"de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017;21(1):38.","journal-title":"Crit Care"},{"issue":"12","key":"10747_CR27","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/jac\/dkad327","volume":"78","author":"AK Smekal","year":"2023","unstructured":"Smekal AK, Furebring M, Lipcsey M, Giske CG. Swedish multicentre study of target attainments with beta-lactams in the ICU: which MIC parameter should be used? J Antimicrob Chemother. 2023;78(12):2895\u2013901.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10747_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73(3):564\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"10747_CR29","unstructured":"ZorginstituutNederland. Guideline for conducting economic evaluations in healthcare [in Dutch: richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg]. 2024. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"issue":"1","key":"10747_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/FTD.0000000000000891","volume":"44","author":"TMJ Ewoldt","year":"2022","unstructured":"Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, et al. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022;44(1):224\u20139.","journal-title":"Ther Drug Monit"},{"key":"10747_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2288-14-20","volume":"14","author":"BC Kahan","year":"2014","unstructured":"Kahan BC. Accounting for centre-effects in multicentre trials with a binary outcome - when, why, and how? BMC Med Res Methodol. 2014;14:20.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10747_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12874-016-0281-5","volume":"17","author":"E Kontopantelis","year":"2017","unstructured":"Kontopantelis E, White IR, Sperrin M, Buchan I. Outcome-sensitive multiple imputation: a simulation study. BMC Med Res Methodol. 2017;17(1):2.","journal-title":"BMC Med Res Methodol"}],"updated-by":[{"DOI":"10.1186\/s12879-025-10877-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10747-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:09:15Z","timestamp":1768342155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-10747-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10747"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10747-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-025-10877-8","URL":"https:\/\/doi.org\/10.1186\/s12879-025-10877-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial received ethical approval from Medical Ethics Committee Oost-Nederland on September 30th 2024 (EU_CT 2024\u2013512950-13\u201300).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}